Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM [PDF]
JACC: Heart FailureOlivotto, I.
core +2 more sources
Emerging Medical Treatment for Hypertrophic Cardiomyopathy [PDF]
, 2021 Hypertrophic cardiomyopathy (HCM) is a common myocardial disease characterized by otherwise unexplained left ventricular hypertrophy. The main cause of disabling symptoms in patients with HCM is left ventricular outflow tract (LVOT) obstruction.
Bacchi, Beatrice +9 more
core +1 more source
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy [PDF]
, 2022 Cardiomyopathies have unresolved genotype–phenotype relationships and lack disease-specific treatments. Here we provide a framework to identify genotype-specific pathomechanisms and therapeutic targets to accelerate the development of precision medicine.
Bueno-Orovio, Alfonso +11 more
core +2 more sources
A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors [PDF]
, 2023 In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors
Olivotto Iacopo +2 more
core +1 more source
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy [PDF]
, 2023 Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy
Olivotto, Iacopo
core +4 more sources
Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy [PDF]
, 2020 BACKGROUND: Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; however, there are no proven pharmacological therapies.
Bach, Richard G, et al.,, Ho, Carolyn Y
core +2 more sources
Exposure-Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM. [PDF]
J Clin PharmacolAbstract Mavacamten, a cardiac myosin inhibitor, is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, and coadministration with strong CYP3A4 or CYP2C19 inhibitors was contraindicated in patients with obstructive hypertrophic cardiomyopathy (HCM) in the US Prescribing Information. This study assessed the safety and efficacy
Merali S +7 more
europepmc +2 more sources
The Egyptian Heart Journal, 2023 Background Hypertrophic cardiomyopathy (HCM) is a hereditary myocardial disorder, often due to sarcomere gene mutations, characterized by the left ventricular hypertrophy. Current treatments offer symptomatic relief but lack specificity.
Hussain Sohail Rangwala +5 more
doaj +1 more source
Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply [PDF]
The Lancet, 2021 reply to ...
Jacoby D. +4 more
openaire +2 more sources
Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial [PDF]
, 2023 IMPORTANCE: Mavacamten, a cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in the EXPLORER-HCM study.
Olivotto, Iacopo
core +4 more sources